Emtricitabine Tenofovir Disoproxyl Fumarate Aurobindo

Emtricitabine Tenofovir Disoproxil Fumarate Aurobindo is a combination medication used for HIV treatment and prevention. This oral medication is manufactured by Aurobindo Pharma B.V. and is available in the EU market.

Emtricitabine Tenofovir Disoproxil Fumarate is primarily used in the management of HIV infection. It is often prescribed as part of a combination therapy to help control the virus and reduce the risk of HIV transmission. This medication is also used for pre-exposure prophylaxis (PrEP) in individuals at high risk of HIV infection. The active ingredients, emtricitabine and tenofovir disoproxil, work together to inhibit the replication of the HIV virus.

Common effects of Emtricitabine Tenofovir Disoproxil Fumarate may include headache, nausea, diarrhea, and dizziness. Some individuals may experience changes in body fat distribution, such as increased fat in the upper back and neck, or loss of fat in the legs, arms, and face. It is important to discuss any persistent or severe side effects with a healthcare provider.

Emtricitabine Tenofovir Disoproxil Fumarate should be used with caution in individuals with kidney problems, as the medication is primarily excreted by the kidneys. Regular monitoring of kidney function is recommended. Patients with a history of hepatitis B should also be cautious, as the medication can cause a flare-up of the virus. Always follow the advice of a healthcare professional regarding the use of this medication.

Emtricitabine Tenofovir Disoproxil Fumarate may interact with other medications, including those used to treat HIV, hepatitis C, and certain antacids. It is important to inform a healthcare provider about all medications being taken to avoid potential interactions. Alcohol consumption should be moderated, as it may exacerbate some side effects.